Table 1 Characteristics of 13 patients with COVID-19
From: Effect of favipiravir and an anti-inflammatory strategy for COVID-19
Characteristics | Value |
|---|---|
Age, mean (SD), years | 63 (12) |
Male sex, No. (%) | 9 (69) |
Body weight, mean (SD), kg | 70 (21) |
Bronchial asthma No. (%) | 1 (8) |
Diabetes mellitus, No. (%) | 7 (54) |
Hypertension, No. (%) | 8 (62) |
Sleep apnea syndrome, No. (%) | 3 (23) |
APACHE II score, median [IQR] | 9 [5, 13] |
PaO2/FIO2 ratio at intubation, mean (SD) | 210 (73) |
D-dimer on admission, median [IQR], ng/mL | 1.3 [1.0, 2.8] |
CRP on admission, median [IQR], mg/dL | 11.9 [4.6, 19.6] |
PCT on admission, median [IQR], ng/mL | 0.21 [0.09, 0.54] |
Presepsin on admission, median [IQR], pg/mL | 440 [302, 763] |
IL-6 on admission, median [IQR], pg/mL | 77.5 [35.7, 161.9] |
Time from first symptom appearance, mean (SD), day | |
 Favipiravir | 8.7 (2.6) |
 Heparin | 10.8 (3.9) |
 Steroid | 13.2 (2.9) |
 Dexmedetomidine | 10.7 (4.1) |
 Intubation | 9.9 (3.3) |
ECMO, No. (%) | 1 (8) |
Ventilator days, median [IQR], days | 11 [9, 12] |
Outcome, No. (%) | |
 Survived | 12 (92) |
 Dead | 1 (8) |